期刊文献+

复发性生殖器疱疹的临床治疗分析 被引量:2

Clinical Analysis on the Treatment of Recurrent Genital Herpes
下载PDF
导出
摘要 目的:探讨复发性生殖器疱疹(RGH)患者的临床表现,为临床治疗提供可靠的参考信息。方法选取我院2010-2014年的70例复发性生殖器疱疹患者来进行分析,为患者进行了胸腺肽α1注射,1.6 mg/次,两天一次;进行8次治疗后为两周一次,再次治疗8次,然后一周一次,再治疗8次。结果全部患者中共有65例成功治愈,比例为92.9%,有5例复发病例。这70例患者进行了HIV检查,结果为阴性。结论胸腺肽α1可以对患者的先天和后天抗病毒免疫功能起到调整,增强患者的免疫系统,可以用于治疗复发性生殖器疱疹疾病。 Objective To investigate the recurrent genital herpes(RGH)patients with clinical manifestations,and provide reliable reference information for clinical treatment. Methods 70 patients with recurrent genital herpes for analysis in our hospital from 2010 to 2014,injection thymosin alpha 1(1.6 mg)every two days. After 8 time treatment,injection changed for every two weeks and treated again 8 times. Then injection(1.6 mg)changed for every week. Results 65 patients(92.9%)were successful y treated. There were 5 cases of recurrent. The 70 cases were examined by HIV,the result was negative. Conclusion Thymosin alpha 1 can make the patient′s immune system enhanced and treat recurrent genital herpes,by adjusting for patients with congenital and acquired antiviral immune function.
作者 王禹潞
出处 《中国卫生标准管理》 2015年第10期44-45,共2页 China Health Standard Management
关键词 复发性 生殖器疱疹 临床治疗 Recurrent Genital herpes Clinical treatment
  • 相关文献

参考文献4

二级参考文献27

  • 1朱邦勇,李民,文春梅,赵秀梅,甘泉,覃善列,梁月金.梅毒合并其他性传播疾病和/或HIV感染情况的分析[J].中国皮肤性病学杂志,2007,21(6):355-356. 被引量:25
  • 2Reitano M,Tyring S,Lang W,et al.Valaciclovir for the suppression of recurrent genital herpes simplex vims infection:a largescale dose range-finding study.International Valaciclovir HSV Study Group.J Infect Dis,1998,178(3):603-610.
  • 3Weller S,Blum MR,Doucette M,et al.Pharmacokinetics of the acyclovir pro-drug valaciclovir after escalating single-and multiple-dose administration to normal volunteers.Clin Pharmacol Ther,1993,54(6):595-605.
  • 4Romanowski B,Marina RB,Roberts JN.Patients' preference of valacyclovir once-daily suppressive therapy versus twice-daily episodic therapy for recurrent genital herpes:a randomized study.Sex Transm Dis,2003,30(3):226-231.
  • 5Koelle DM, Wald A. Herpes simplex virus: the importance of asymptomatic shedding[J]. J Antimicrob Chemother, 2000, 45 Suppl T3: 1-8.
  • 6Schiffer JT, Corey L. New concepts in understanding genital herpes [J]. Curt Infect Dis Rep, 2009, 11 (6) : 457-464.
  • 7Wald A, Zeh J, Barnum G, et al. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir[J]. Ann Intern Med, 1996, 124(1Pt 1): 8-15.
  • 8Corey L. Challenges in genital herpes simplex virus management[J]. J Infect Dis, 2002, 186 Suppl 1 : S29-S33.
  • 9Reitano M, Tyring S, Lang W, et al. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: a large-scale dose range-finding study. International Valaciclovir HSV Study Group[J]. J Infect Dis, 1998, 178(3): 603-610.
  • 10Weller S, Blum MR, Doucette M, et al. Pharmacokineties of the acyclovir pro-drug valaciclovir after escalating singleand multipledose administration to normal volunteers[J]. Clin Pharmacol Ther, 1993, 54(6): 595-605.

共引文献38

同被引文献8

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部